eisai to present data on oncology pipeline and products at asco annual meeting – eisai china lnc.-开元游戏大厅app版本合集

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate (multikinase inhibitor, product name: lenvima®, “lenvatinib”) and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: halaven®, “eribulin”) will be given at the american society of clinical oncology (asco20 virtual scientific program*), from may 29 to 31, 2020.
* presentation materials will be made available on demand via asco’s website at 8:00 am on may 29th (et).

at this year’s meeting, the final results of two studies will be presented on the combination therapy of lenvatinib with the anti-pd-1 antibody keytruda® (generic name: pembrolizumab, “pembrolizumab”) from merck & co., inc., kenilworth, n.j., u.s.a. (known as msd outside the united states and canada). one is the oral presentation of the metastatic renal cell carcinoma cohort (abstract number: 5008) of study 111 / keynote-146, and the other is the poster discussion presentation of the first-line therapy for unresectable hepatocellular carcinoma (abstract number: 4519) in study 116 / keynote-524**.
**this release discusses investigational compounds and investigational uses for fda-approved products. it is not intended to convey conclusions about efficacy and safety. there is no guarantee that any investigational compounds and investigational uses of fda-approved products will successfully complete clinical development or gain fda approval.

in march 2018, eisai and merck & co., inc., kenilworth, n.j., u.s.a., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards curing cancer. eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals.